These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 23604250)

  • 1. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases.
    Olsen KR; Hansen C; Abrahamsen B
    Osteoporos Int; 2013 Oct; 24(10):2639-47. PubMed ID: 23604250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to osteoporosis medications amongst Singaporean patients.
    Cheen MH; Kong MC; Zhang RF; Tee FM; Chandran M
    Osteoporos Int; 2012 Mar; 23(3):1053-60. PubMed ID: 21503813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study.
    Sahota O; Narayanasamy M; Bastounis A; Paskins Z; Bishop S; Langley T; Gittoes N; Davis S; Baily A; Holmes M; Leonardi-Bee J
    Health Technol Assess; 2024 Apr; 28(21):1-169. PubMed ID: 38634483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.
    Hadji P; Claus V; Ziller V; Intorcia M; Kostev K; Steinle T
    Osteoporos Int; 2012 Jan; 23(1):223-31. PubMed ID: 21308365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
    Pazianas M; Abrahamsen B; Wang Y; Russell RG
    Osteoporos Int; 2012 Dec; 23(12):2873-84. PubMed ID: 22431012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-osteoporotic therapy in Denmark--predictors and demographics of poor refill compliance and poor persistence.
    Hansen C; Pedersen BD; Konradsen H; Abrahamsen B
    Osteoporos Int; 2013 Jul; 24(7):2079-97. PubMed ID: 23179576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
    Martin KE; Yu J; Campbell HE; Abarca J; White TJ
    J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual effect after oral bisphosphonate treatment and healthy adherer effects--the Swedish Adherence Register Analysis (SARA).
    Ström O; Landfeldt E; Garellick G
    Osteoporos Int; 2015 Jan; 26(1):315-25. PubMed ID: 25297890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between osteoporosis treatment change and adherence, incident fracture, and total healthcare costs in a Medicare Advantage Prescription Drug plan.
    Ward MA; Xu Y; Viswanathan HN; Stolshek BS; Clay B; Adams JL; Kallich JD; Fine S; Saag KG
    Osteoporos Int; 2013 Apr; 24(4):1195-206. PubMed ID: 23100119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
    Lindsay R; Watts NB; Lange JL; Delmas PD; Silverman SL
    Osteoporos Int; 2013 Aug; 24(8):2345-52. PubMed ID: 23612793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.
    Imaz I; Zegarra P; González-Enríquez J; Rubio B; Alcazar R; Amate JM
    Osteoporos Int; 2010 Nov; 21(11):1943-51. PubMed ID: 19967338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to treatment of primary osteoporosis and its association to fractures--the Swedish Adherence Register Analysis (SARA).
    Landfeldt E; Ström O; Robbins S; Borgström F
    Osteoporos Int; 2012 Feb; 23(2):433-43. PubMed ID: 21286686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan.
    Soong YK; Tsai KS; Huang HY; Yang RS; Chen JF; Wu PC; Huang KE
    Osteoporos Int; 2013 Feb; 24(2):511-21. PubMed ID: 22588182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women.
    Rabenda V; Mertens R; Fabri V; Vanoverloop J; Sumkay F; Vannecke C; Deswaef A; Verpooten GA; Reginster JY
    Osteoporos Int; 2008 Jun; 19(6):811-8. PubMed ID: 17999022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of osteoporosis medications for preventing periprosthetic fractures following femoral neck fracture indicated hip arthroplasty: a break-even analysis.
    Agarwal AR; Kinnard MJ; Murdock C; Zhao AY; Ahiarakwe U; Cohen JS; Moseley KF; Golladay GJ; Thakkar SC
    Osteoporos Int; 2024 Jul; 35(7):1223-1229. PubMed ID: 38619605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examining the Effect of Medication Adherence on Risk of Subsequent Fracture Among Women with a Fragility Fracture in the U.S. Medicare Population.
    Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1178-1190. PubMed ID: 29083977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan.
    Moriwaki K; Mouri M; Hagino H
    Osteoporos Int; 2017 Jun; 28(6):1939-1950. PubMed ID: 28265718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in persistence among different weekly oral bisphosphonate medications.
    Sheehy O; Kindundu CM; Barbeau M; LeLorier J
    Osteoporos Int; 2009 Aug; 20(8):1369-76. PubMed ID: 19020921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management.
    Ganda K; Schaffer A; Pearson S; Seibel MJ
    Osteoporos Int; 2014 Apr; 25(4):1345-55. PubMed ID: 24445732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are long-term bisphosphonate users a reality? Dose years for current bisphosphonate users assessed using the danish national prescription database.
    Abrahamsen B
    Osteoporos Int; 2013 Jan; 24(1):369-72. PubMed ID: 22572963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.